within Pharmacolibrary.Drugs.ATC.D;

model D01AE11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Haloprogin is a synthetic antifungal agent that was formerly used topically to treat dermatophytosis (tinea infections of the skin), including athlete's foot, jock itch, and ringworm. It is no longer widely used or approved in most countries due to better tolerated and more effective alternatives.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies or parameter estimates for haloprogin were found in the literature or major pharmacokinetic databases.</p><h4>References</h4><ol><li><p>Hermann, HW (1973). Clinical safety of haloprogin, a new topical antimicrobial. <i>Clinical pharmacology and therapeutics</i> 14(1) 100–103. DOI:<a href=&quot;https://doi.org/10.1002/cpt1973141100&quot;>10.1002/cpt1973141100</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4683067/&quot;>https://pubmed.ncbi.nlm.nih.gov/4683067</a></p></li><li><p>Fukuyasu, H, et al., &amp; Yamaguchi, H (1989). In vivo activity and metabolic fate of 2-(2,3,3-triiodoallyl)tetrazole (ME1401), a novel antifungal agent. <i>Drugs under experimental and clinical research</i> 15(8) 335–347. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2598775/&quot;>https://pubmed.ncbi.nlm.nih.gov/2598775</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D01AE11;
